Key result
Licochalcone A improves glycolipid metabolism in T2DM mice via PPAR signaling blocked by antibiotics.
Why the study?
The mechanisms by which licochalcone A regulates glycolipid metabolism in type 2 diabetes mellitus remain unclear.
Does licochalcone A improve glycolipid metabolism in db/db mice?
Does licochalcone A improve glycolipid metabolism in db/db mice?
Licochalcone A improves glucose and lipid metabolism in a T2DM mouse model through gut microbiota modulation and PPAR signaling activation.
Hypothesis-generating for licochalcone A in T2DM models; leaves open translation to human therapy.
. The combined analysis of liver metabolomics and liver proteomics indicated that LicA altered the intestinal microbiota metabolite hypotaurine through p-75-a5, and hypotaurine played a bridging role between p-75-a5 and glycolipid metabolism in T2DM. Through multi-omics joint analysis and WB experimental verification, the results showed that LicA activates the PPAR signaling pathway to improve glucose lipid metabolism disorders in T2DM. More importantly, after treating db/db mice with antibiotics, the beneficial effects of LicA were blocked, indicating that the gut microbiota plays a key role in LicA's improvement of glucose and lipid metabolism in T2DM. In conclusion, this study revealed a new mechanism by which LicA improves T2DM glucose and lipid metabolism disorder, and the potential improvement of LicA's glucose and lipid metabolism in T2DM may be related to the change of p-75-a5 targeting hypotaurine.
No takes yet. Share an insight, caveat, or question.
Gao et al. (2025) studied Type 2 Diabetes Mellitus (T2DM). Licochalcone A (LicA) was evaluated on Glucose and lipid metabolism. Licochalcone A improved glucose and lipid metabolism disorders in db/db mice with T2DM by activating the PPAR signaling pathway, an effect that was blocked by antibiotic treatment.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: